Milestone Pharmaceuticals Statistics
Share Statistics
Milestone Pharmaceuticals has 53.46M
shares outstanding. The number of shares has increased by 0.18%
in one year.
| Shares Outstanding | 53.46M |
| Shares Change (YoY) | 0.18% |
| Shares Change (QoQ) | 0.05% |
| Owned by Institutions (%) | 37.09% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 6,586 |
| FTD / Avg. Volume | 0.25% |
Short Selling Information
The latest short interest is 2.37M, so 4.43% of the outstanding
shares have been sold short.
| Short Interest | 2.37M |
| Short % of Shares Out | 4.43% |
| Short % of Float | 4.47% |
| Short Ratio (days to cover) | 1.14 |
Valuation Ratios
The PE ratio is -3.54 and the forward
PE ratio is -0.91.
Milestone Pharmaceuticals's PEG ratio is
0.07.
| PE Ratio | -3.54 |
| Forward PE | -0.91 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 11.17 |
| P/FCF Ratio | -5.08 |
| PEG Ratio | 0.07 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Milestone Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.1,
with a Debt / Equity ratio of 4.17.
| Current Ratio | 9.1 |
| Quick Ratio | 9.1 |
| Debt / Equity | 4.17 |
| Debt / EBITDA | -1.3 |
| Debt / FCF | -1.9 |
| Interest Coverage | 11.76 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,258,151.52 |
| Employee Count | 33 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -259K |
| Effective Tax Rate | 0.62% |
Stock Price Statistics
The stock price has increased by -32.95% in the
last 52 weeks. The beta is 0.86, so Milestone Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | -32.95% |
| 50-Day Moving Average | 1.36 |
| 200-Day Moving Average | 1.63 |
| Relative Strength Index (RSI) | 47.29 |
| Average Volume (20 Days) | 2,633,405 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.1M |
| Net Income | -41.52M |
| EBITDA | -42.1M |
| EBIT | -38.2M |
| Earnings Per Share (EPS) | -0.67 |
Full Income StatementBalance Sheet
The company has 25.31M in cash and 54.8M in
debt, giving a net cash position of -29.48M.
| Cash & Cash Equivalents | 25.31M |
| Total Debt | 54.8M |
| Net Cash | -29.48M |
| Retained Earnings | -367.55M |
| Total Assets | 75.5M |
| Working Capital | 65.8M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -28.85M
and capital expenditures -33K, giving a free cash flow of -28.88M.
| Operating Cash Flow | -28.85M |
| Capital Expenditures | -33K |
| Free Cash Flow | -28.88M |
| FCF Per Share | -0.46 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
